{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-049661","form_type":"8-K","ticker":"CAMP","cik":"0001736730","company_name":"Camp4 Therapeutics Corp","filed_at":"2026-07-27T11:01:41+00:00","discovered_at":"2026-07-27T11:05:00.212404+00:00","generated_at":"2026-07-27T11:05:23.302416+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CAMP4 receives Australian TGA clearance for CMP-002 Phase 1/2 trial; triggers $50M second closing","bullets":["TGA and HREC clearance to initiate first-in-human Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder.","Milestone triggers second closing of September 2025 private placement; up to $50M gross proceeds.","Second closing expected on or about August 3, 2026; up to 32.7M shares (or pre-funded warrants) to be issued.","Investors committed include Coastlands Capital, Janus Henderson, Balyasny, Vivo Capital, 5AM Ventures, Adage, Trails Edge, CURE SYNGAP1.","Australia selected as first site; company pursuing additional international regulatory filings."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-049661","json":"https://secwatch.observer/filing/0001628280-26-049661.json","markdown":"https://secwatch.observer/filing/0001628280-26-049661.md","text":"https://secwatch.observer/filing/0001628280-26-049661.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/0001628280-26-049661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736730/000162828026049661/camp-20260727.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-27T11:05:23.302416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}